Bio Vitos Pharma Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Jesper Birgemo
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 1.0% |
| Management average tenure | no data |
| Board average tenure | 2.3yrs |
CEO
Jesper Birgemo (46 yo)
less than a year
Tenure
Mr. Jesper Birgemo serves as Chief Executive Officer at Bio Vitos Pharma AB (publ) Since November 2023. He served as Chief Executive Officer and Executive Director of ExeoTech Invest AB (publ) since July 2...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy Director | 9.3yrs | no data | no data | |
| Director | 2.3yrs | no data | 0.30% SEK 159.9k | |
| Independent Director | 6.3yrs | no data | 0.015% SEK 7.7k | |
| Director | no data | no data | 0.069% SEK 36.7k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| President of the Board | 1.3yrs | no data | no data | |
| Director | 1.3yrs | no data | no data |
2.3yrs
Average Tenure
50yo
Average Age
Experienced Board: BIOVIT's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.